As manufacturers continue to invest more in rapid testing, the PCR and real-time PCR molecular diagnostics market are expected to achieve growth over the long term. The market was valued at $4 billion last year and boosted by COVID-19 and emergency use authorizations, it is anticipated to exceed $6 billion by 2030, according to a recent report by research firm Fact.MR.. Thus far North America is leading regional markets for the technology and is followed by Europe. Other diagnostic segments expected to grow include oncology, which will be driven by more patients an investment in modernizing healthcare centers.

Key players in the PCR and real-time PCR molecular diagnostics market include Abbott Laboratories, Elekta AB Bio-Rad Laboratories Inc., bioMerieux SA, Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, F.Hoffmann-La Roche Ltd., Qiagen NV, Hologic Inc, Grifols SA, Genomic Health, and Seegene Inc.